<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>drug development on FinanClub</title>
    <link>https://finan.club/tags/drug-development/</link>
    <description>Recent content in drug development on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 22 Mar 2024 09:05:43 +0000</lastBuildDate><atom:link href="https://finan.club/tags/drug-development/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Fri, 22 Mar 2024 09:05:43 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:73
Chances: AstraZeneca&amp;rsquo;s acquisition of Fusion Biopharma for $21 per share in cash, along with a contingent value right of $3 per share, indicates strategic growth and expansion in the pharmaceutical industry. GSK&amp;rsquo;s plan to lower the prices of its inhaled respiratory products to $35 per month in the US in 2025 could lead to increased market share and customer loyalty.</description>
    </item>
    
  </channel>
</rss>
